Medtech Insight: C₂N Diagnostics Plasma-Based Biomarker Test Covered by Medtech Insight

Media Coverage

In a 9 page report Medtech Insight outlines the current state of the field of Alzheimer's disease diagnostic.Read the report: "Alzheimer's Disease: Moving Toward The Era Of Diagnostic Certainty".

Previous

Antibody helps detect protein implicated in Alzheimer’s, other diseases
Next

C₂N Diagnostics Makes Three New Hires to Speed Commercialization of Diagnostics and Theranostics